AC Immune 将来の成長

Future 基準チェック /56

AC Immuneは、54.7%と32%でそれぞれ年率54.7%で利益と収益が成長すると予測される一方、EPSはgrowで55.4%年率。

主要情報

54.7%

収益成長率

55.4%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	32.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:IMR - アナリストの将来予測と過去の財務データ ( )CHF Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	67	-27	50	-71	3
12/31/2025	62	-23	25	-46	4
12/31/2024	27	-53	-57	29	3
9/30/2024	41	-40	43	44	N/A
6/30/2024	15	-61	44	45	N/A
3/31/2024	15	-55	-43	-43	N/A
12/31/2023	15	-54	-61	-60	N/A
9/30/2023	0	-68	-62	-62	N/A
6/30/2023	4	-67	-62	-62	N/A
3/31/2023	4	-69	-68	-67	N/A
12/31/2022	4	-71	-75	-74	N/A
9/30/2022	4	-73	-76	-74	N/A
6/30/2022	N/A	-76	-77	-75	N/A
3/31/2022	N/A	-75	-74	-71	N/A
12/31/2021	N/A	-73	-68	-66	N/A
9/30/2021	1	-71	-70	-67	N/A
6/30/2021	2	-74	-71	-68	N/A
3/31/2021	3	-71	-69	-67	N/A
12/31/2020	15	-62	-61	-60	N/A
9/30/2020	15	-62	-54	-53	N/A
6/30/2020	47	-25	-22	-20	N/A
3/31/2020	48	-26	-22	-20	N/A
12/31/2019	110	45	53	55	N/A
9/30/2019	111	50	55	56	N/A
6/30/2019	80	18	26	27	N/A
3/31/2019	81	24	34	35	N/A
12/31/2018	7	-51	-46	-44	N/A
9/30/2018	22	-32	-28	-26	N/A
6/30/2018	21	-27	N/A	-22	N/A
3/31/2018	20	-29	N/A	-24	N/A
12/31/2017	20	-26	N/A	-22	N/A
9/30/2017	5	-35	N/A	-35	N/A
6/30/2017	6	-36	N/A	-19	N/A
3/31/2017	25	-10	N/A	-10	N/A
12/31/2016	23	-7	N/A	-6	N/A
9/30/2016	22	-8	N/A	-4	N/A
6/30/2016	45	21	N/A	21	N/A
3/31/2016	39	17	N/A	16	N/A
12/31/2015	39	20	N/A	44	N/A
9/30/2015	65	46	N/A	45	N/A
6/30/2015	41	21	N/A	8	N/A
3/31/2015	28	10	N/A	7	N/A
12/31/2014	30	11	N/A	-18	N/A
12/31/2013	9	-11	N/A	-20	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IMRは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: IMR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: IMR今後 3 年以内に収益を上げることが予想されます。

収益対市場: IMRの収益 ( 32% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: IMRの収益 ( 32% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IMRの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AC Immune 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

New major risk - Revenue and earnings growth

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

New major risk - Revenue and earnings growth

AC Immune SA Announces Executive Changes

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

New 90-day high: €5.57

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: €5.17

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

AC Immune Sa Appoints Carl H. June as Board of Directors

AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer

Revenue beats expectations

Third quarter 2020 earnings released: CHF0.26 loss per share

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

New 90-day low: €3.83

AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

New 90-day low: €4.25

First half earnings released

New 90-day high - €7.95

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘